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Tumor immunityThe present study was undertaken to detect circulating IgG antibodies to peptide antigens derived
from baculoviral IAP repeat-containing protein 5 isoform 2 (BIRC5) and myc proto-oncogene pro-
tein (MYC) in cervical cancer. A total of 107 female patients with cervical cancer of stages I and II,
and 130 healthy female subjects were recruited for analysis of circulating IgG antibodies to BIRC5
and MYC. Student’s t-test showed signiﬁcant differences in circulating levels of anti-BIRC5 IgG
(t = 4.27, df = 235, P < 0.0001) and anti-MYC IgG (t = 3.51, df = 232, P = 0.0005) between the patient
group and the control group. Receiver operating characteristic (ROC) analysis showed an area under
the ROC curve (AUC) of 0.67 with sensitivity of 23.4% against speciﬁcity of 90% for the anti-BIRC5 IgG
assay and an AUC of 0.66 with sensitivity of 9.4% against speciﬁcity of 90.6% for the anti-MYC IgG
assay. Analysis of quality control samples gave an inter-assay deviation of 8.9% in the anti-BIRC5
IgG assay and 9.0% in the anti-MYC IgG assay. This work suggests that anti-BIRC5 IgG could serve
as a biomarker for early diagnosis of cervical cancer although a panel of such tumor-associated anti-
gens is needed to develop a highly sensitive test.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cervical cancer is a common malignant condition with cumula-
tive risk of 0.9% in women and the fourth leading cause of cancer
death in female subjects worldwide [6]. Etiologically, cervical can-
cer is a delayed consequence of human papillomavirus (HPV) infec-
tion. While HPV DNA testing could reduce the risk of developing
cervical cancer, early diagnosis of this type of malignancy is still
needed. Circulating autoantibodies have been suggested to serve
as potential biomarkers for early diagnosis of cancer
[13,17,8,5,11,12]. A successful test has been developed for earlydiagnosis of lung cancer [9,3,7]. It thus makes it possible to identify
a panel of useful tumor-associated antigens (TAAs) for the develop-
ment of antibody-based test for early diagnosis of cervical cancer.
Increased expression of baculoviral IAP repeat-containing protein 5
isoform 2 (BIRC5) and myc proto-oncogene protein (MYC) have
been reported in cervical cancer [1,10,20]; to our knowledge, it
has not been documented whether antibodies against BIRC5 and
MYC proteins are also increased in this malignant disease.
Accordingly, the present work was undertaken to detect circulating
IgG antibodies for BIRC5 and MYC among patients with cervical
cancer and control subjects in a Chinese population.
2. Materials and methods
2.1. Subjects
A total of 107 female patients aged 48.8 ± 9.2 years, who were
newly diagnosed as having cervical cancer, were recruited for this
study by the Department of Gynecology and Obstetrics, Second
Hospital of Jilin University, Changchun, China. Their diagnoses
were made based on the Pap smear and histological conﬁrmation
and the tumors were staged by the International Federation of
Gynecology and Obstetrics (FIGO) staging system. In this study,
Table 2
The levels of IgG antibodies to BIRC5 and MYC in cervical cancer.
Antibody1 Patient (n) Control (n) t P
BIRC5
Squamous 1.30 ± 0.22 (91) 1.17 ± 0.20 (130) 4.51 <0.0001
Others 1.22 ± 0.23 (130) 1.17 ± 0.20 (130) 0.95 0.344
Combined 1.29 ± 0.22 (107) 1.17 ± 0.20 (130) 4.27 <0.0001
MYC
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and those at stages III and IV were excluded. Pathological examina-
tion conﬁrmed that of these 107 patients, 91 had squamous cell
carcinoma (SCC) and 16 had adenocarcinoma, adenosquamous car-
cinoma or small cell carcinoma. Plasma samples were taken prior
to any anticancer treatment. One hundred and thirty female sub-
jects aged 50.9 ± 5.4 years, were also recruited as controls from a
local community. Clinical interview and the Pap smear were
applied to rule out those control subjects who had suffered from
cervical cancer and any other malignant diseases. All the subjects
were of Chinese Han origin and all gave written informed consent
to attend this study as approved by the Ethics Committee of Jilin
University Second Hospital.
2.2. Antibody testing
Enzyme-linked immune-sorbent assay (ELISA) was developed
in-house using linear peptide antigens derived from human
BIRC5 and MYC proteins. The linear peptide antigens were
designed according to the computational prediction of HLA-II epi-
topes [15,19] and their amino acid sequences are given in Table 1;
a 28-mer peptide derived from a goat alpha-lactalbumin protein
(Accession 1FKV_A) was used as the control antigen (Table 1). All
peptide antigens were synthesized by a solid-phase chemical
method and dissolved in 67% acetic acid to obtain a concentration
of 5 mg/ml as stock solution stored at 20 C. The working solution
was made by diluting the stock solution with phosphate-buffered
saline (PBS)-based coating buffer (P4417, Sigma–Aldrich) to
10 lg/ml for each of 2 human peptide antigens (hAg) and to
20 lg/ml for the control antigen. Costar 96-Well Microtiter EIA
Plate (ImmunoChemistry Technologies, USA) was half-coated in
0.1 ml/well of each hAg and half-coated in 0.1 ml/well of the con-
trol antigen, and then incubated at 4 C overnight. After the anti-
gen-coated plate was washed at least 3 times with PBS
containing 0.05% Tween-20 (PBS-T), 100 ll plasma sample diluted
1:200 in Assay Buffer (DS98200, Life Technologies) was added to
the sample wells and 100 ll Assay Buffer was added to the nega-
tive control (NC) wells. Following 3 h incubation at room tempera-
ture, plates were washed at least 3 times and 200 ll peroxidase-
conjugated goat antibody to human IgG (A8667, Sigma–Aldrich)
diluted 1:30,000 in Assay Buffer were added to each well. After
incubation at room temperature for an hour, color development
was initiated by adding 100 ll Stabilized Chromogen (SB02, Life
Technologies) and terminated 25 min later by adding 50 ll Stop
Solution (SS04, Life Technologies). The measurement of the optical
density (OD) was completed within 10 min at 450 nm with a refer-
ence wavelength of 620 nm. To reduce the interference from a non-
speciﬁc signal produced by passive absorption of various IgG
antibodies in plasma to the surface of 96-well microplate, a speciﬁc
binding index (SBI) was used to express the levels of circulating
antibodies to BIRC5 and MYC. Each sample was tested in duplicate
and SBI was calculated as follows:
SBI ¼ ðODhAg  ODNCÞ=ðODcontrol antigen  ODNCÞTable 1
Information of peptide antigens used for development of ELISA antibody test.
Antigen Sequence (N? C) NCBI accession Working
solution
(lg/ml)
BIRC5 H-dﬂkdhristfknwlhhfqglfpgatslpv-OH NP_001012270 10
MYC H-rvkldsvrvlrqisnnrkcfellptpplsps-OH NP_002458 10
Control H-vfqklkdlkdyggvslpewvkiafhtsg-OH 1FKV_A 202.3. Data analysis
The experimental data were expressed as mean ± standard
deviation (SD) in SBI. IBM SPSS Statistics 21.0 software was used
to perform the Student’s t-test for the differences in SBI between
the patient group and the control group, and the receiver operating
characteristic (ROC) analysis to work out the area under the ROC
curve (AUC) with 95% conﬁdence interval (CI) and the sensitivity
of the ELISA antibody test against a speciﬁcity of >90%. To mini-
mize intra-assay deviation, the ratio of the difference between
duplicate sample OD values to their sum was used to assess the
assay accuracy. If the ratio was found to be >10%, the test of this
sample was treated as being invalid and would not be used for data
analysis. The inter-assay deviation was estimated using pooled
plasma samples, namely quality control (QC) samples, which were
randomly collected from >200 healthy subjects and tested on every
96-well plate.
3. Results
Student’s t-test showed signiﬁcant differences in circulating
levels (SBI) of the anti-BIRC5 IgG (t = 4.27, df = 235, P < 0.0001)
and the anti-MYC IgG (t = 3.51, df = 232, P = 0.0005) between the
patient group and the control group; SCC mainly contributed to
the signiﬁcant chance of circulating IgG levels (Table 2). ROC analy-
sis showed that the anti-BIRC5 IgG assay produced an AUC of 0.67
(95%CI 0.60–0.74) with sensitivity of 23.4% against speciﬁcity of
90% and the anti-MYC IgG assay produced an AUC of 0.66 (95%CI
0.59–0.73) with sensitivity of 9.4% against speciﬁcity of 90.6%
(Table 3 and Fig. 1). Analysis of QC samples gave an inter-assay
deviation of 8.9% for anti-BIRC5 IgG assay and 9.0% for anti-MYC
IgG assay.
4. Discussion
The present work recruited patients with early stage cervical
cancer and revealed a signiﬁcant increase in circulating antibodies
to peptide antigens derived from BIRC5 and MYC proteins
(Table 2). However, ROC analysis suggests that anti-BIRC5 IgG
instead of anti-MYC IgG could serve as a biomarker for early
diagnosis of this malignancy as the anti-MYC IgG assay had a low
sensitivity (Table 3). Based on the analysis of QC samples, theTable 3
ROC analysis of circulating IgG to BIRC5 and MYC in cervical cancer.
Antibody AUC 95%CI SE Sensitivity (%) Speciﬁcity (%)
BIRC5 0.67 0.60–0.74 0.036 23.4 90.0
MYC 0.66 0.59–0.73 0.036 9.4 90.6
Squamous 1.42 ± 0.28 (90) 1.28 ± 0.27 (128) 3.57 0.0004
Others 1.36 ± 0.23 (16) 1.28 ± 0.27 (128) 1.02 0.310
Combined 1.41 ± 0.28 (106) 1.28 ± 0.27 (128) 3.51 0.0005
1 Data were expressed as mean ± SD in SBI.
Fig. 1. The area under the ROC curve of circulating IgG autoantibodies to BIRC5 and MYC in patients with cervical cancer. (A) The anti-BIRC5 IgG assay produced an AUC of
0.67 (95%CI 0.60–0.74) with sensitivity of 23.4% against speciﬁcity of 90%. (B) The anti-MYC IgG assay produced an AUC of 0.66 (95%CI 0.59–0.73) with sensitivity of 9.4%
against speciﬁcity of 90.6%.
200 Y. Xu et al. / FEBS Open Bio 5 (2015) 198–201anti-BIRC5 IgG assay gave an inter-assay deviation of 8.9% and the
anti-MYC IgG assay gave that of 9.0%, suggesting that this antibody
test had a very good reproducibility.
BIRC5 is the inhibitor of apoptosis (IAP) family member, which
plays a crucial role in mitosis and in protecting against apoptotic
cell death. The BIRC5-knockout mice showed an extensive
overexpression of the proteins related to cellular maintenance,
organization and protein synthesis [2]. It is possible that increased
circulating anti-BIRC5 IgG may affect apoptosis of many types of
cells in the body and facilitate the transformation of normal cells
to malignant cells. The mechanism behind an increase in anti-
BIRC5 IgG levels is unknown, but it has been proposed that
humoral immune responses to TAAs may result from a self-
immunization process linked to increased immunogenicity of
TAAs during malignant transformation, including antigen mutation
[16], overexpression [4], altered antigen folding [14] and aberrant
degradation [18]. Further investigation will clarify the complicated
mechanism involved in triggering the secretion of anti-BIRC5 IgG
antibodies in cervical cancer.5. Conclusion
Circulating IgG antibodies to the linear peptide antigens derived
from the BIRC5 protein could serve as a biomarker for early diagno-
sis of cervical cancer although a panel of such tumor-associated
antigens is needed to develop a highly sensitive test.
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